Today, is a cool day for 2 reasons. First, today’s date is 10/11/12. Nice and consecutive.
Plus, we are issuing an update on Nuvilex (OTCQB – NVLX)for the first time in a while. The Company released results of a second Phase 2 trial for pancreatic cancer that we believe are even better than the first one.
I know investors are ambivalent or downright dismissive of news and so the stock has gone nowhere recently. However, I defy anyone to read through results and compare the progress to the current market cap, and tell me the stock is not incredibly cheap.
Savvy investors and traders will pounce while the rest of the Street ignores NVLX and they could be well rewarded as more milestone events occur.
Why Is This News Important?
The news should be viewed as landmark news by investors for a number of reasons. First, it should be noted that it is not typical for two Phase 2 trials of this type to have been undertaken. Second, much of the key data generated by the first trial was confirmed in the second trial. Furthermore, between the two trials Nuvilex now has significant data on a total of 27 evaluable patients.
Last but not least, the fact that this trial was conducted in multiple sites versus a single site in the other trial, makes the data that much more powerful.
Investors should latch onto these key themes regarding the Nuvilex approach:
This sleepy stock with a game-changing technology and delivery system continues to be overlooked and sometimes even dismissed by investors. Savvy investors will realize the tremendous value inherent in the stock and acquire shares today at a price that will likely be the floor for the stock, going forward. Patient investors will accumulate stock and could be rewarded with a stock trading at $0.50 12-18 months from now. Traders will take advantage of investors’ ambivalence and buy the stock here in order to trade out of it at $0.15 – $0.20 in the coming months, as milestones are reached.
Analyst: Robert Goldman
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.
This report does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.
ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.
For more information, visit our Disclaimer: www.goldmanresearch.com